Literature DB >> 22361358

Risk factors associated with linezolid-nonsusceptible enterococcal infections.

Jessina C McGregor1, Daniel M Hartung, George P Allen, Randy A Taplitz, Robin Traver, Tony Tong, David T Bearden.   

Abstract

Linezolid is one of few treatment options available for vancomycin-resistant enterococci. The present study investigated risk factors for linezolid-nonsusceptible enterococci using a case-control study of 15 cases and 60 control patients. Previous hospitalization, admission to a medical service, comorbidity, and linezolid and sulfonamide therapy were identified as risk factors.
Copyright © 2012 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22361358      PMCID： PMC3644997          DOI： 10.1016/j.ajic.2011.11.005

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN： 0196-6553            Impact factor:   2.918


  9 in total

Review 1.  Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.

Authors:  A D Harris; T B Karchmer; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  2001-03-21       Impact factor: 9.079

2.  Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.

Authors:  J A McKinnell; M Patel; R M Shirley; D F Kunz; S A Moser; J W Baddley
Journal:  Epidemiol Infect       Date:  2010-11-15       Impact factor: 2.451

3.  Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium.

Authors:  Manjunath P Pai; Keith A Rodvold; Paul C Schreckenberger; Ronald D Gonzales; Jennifer M Petrolatti; John P Quinn
Journal:  Clin Infect Dis       Date:  2002-10-28       Impact factor: 9.079

4.  Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli.

Authors:  Anthony D Harris; Matthew H Samore; Marc Lipsitch; Keith S Kaye; Eli Perencevich; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-05-23       Impact factor: 9.079

5.  Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study.

Authors:  Christopher W Crank; Marc H Scheetz; Benjamin Brielmaier; Warren E Rose; Gourang P Patel; David J Ritchie; John Segreti
Journal:  Clin Ther       Date:  2010-09       Impact factor: 3.393

Review 6.  Oxazolidinones: a new class of antibacterials.

Authors:  G E Zurenko; J K Gibson; D L Shinabarger; P A Aristoff; C W Ford; W G Tarpley
Journal:  Curr Opin Pharmacol       Date:  2001-10       Impact factor: 5.547

7.  Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections.

Authors:  Jessina C McGregor; Eli N Perencevich; Jon P Furuno; Patricia Langenberg; Kathleen Flannery; Jingkun Zhu; Jeffrey C Fink; Douglas D Bradham; Anthony D Harris
Journal:  J Clin Epidemiol       Date:  2006-08-10       Impact factor: 6.437

8.  Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus.

Authors:  Jason M Pogue; David L Paterson; A William Pasculle; Brian A Potoski
Journal:  Infect Control Hosp Epidemiol       Date:  2007-11-01       Impact factor: 3.254

9.  Response to emerging infection leading to outbreak of linezolid-resistant enterococci.

Authors:  Marion A Kainer; Rose A Devasia; Timothy F Jones; Bryan P Simmons; Kelley Melton; Susan Chow; Joyce Broyles; Kelly L Moore; Allen S Craig; William Schaffner
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883
  9 in total
  3 in total

Review 1.  Treatment of Vancomycin-Resistant Enterococci: Focus on Daptomycin.

Authors:  Rose M Kohinke; Amy L Pakyz
Journal:  Curr Infect Dis Rep       Date:  2017-10       Impact factor: 3.725

2.  Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus.

Authors:  Matthew H Greene; Bryan D Harris; Whitney J Nesbitt; Marley L Watson; Patty W Wright; Thomas R Talbot; George E Nelson
Journal:  Open Forum Infect Dis       Date:  2018-10-09       Impact factor: 3.835

3.  Hospital outbreak caused by linezolid resistant Enterococcus faecium in Upper Austria.

Authors:  Heidrun Kerschner; Adriana Cabal; Rainer Hartl; Sigrid Machherndl-Spandl; Franz Allerberger; Werner Ruppitsch; Petra Apfalter
Journal:  Antimicrob Resist Infect Control       Date:  2019-09-09       Impact factor: 4.887
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.